The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Potential Role and Rationale for Treatment of Heart Failure with Sodium–Glucose Co-Transporter 2 Inhibitors
Open accessAbstract
Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. Several anti-hyperglycaemic medications have been associated with a concern for worse HF outcomes. More recently, the results of the EMPA-REG OUTCOME trial showed that the sodium–glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was associated with a pronounced and precocious 38% reduction in cardiovascular mortality in subjects with T2DM and established cardiovascular disease [Correction added on 8 September 2017, after first online publication: “32%” in the previous sentence was corrected to “38%”]. These benefits were more related to a reduction in incident HF events rather than to ischaemic vascular endpoints. Several mechanisms have been put forward to explain these benefits, which also raise the possibility of using these drugs as therapies not only in the prevention of HF, but also for the treatment of patients with established HF regardless of the presence or absence of diabetes. Several large trials are currently exploring this postulate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationHeart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Self-citationThe ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationCardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationDiabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Self-citationWing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Self-citationDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Ahmed, A., Rich, M. W., Fleg, J. L., Zile, M. R., Young, J. B., Kitzman, D. W., Love, T. E., Aronow, W. S., Adams, K. F., & Gheorghiade, M. (2006) · Circulation · doi:10.1161/circulationaha.106.628347 · Cited by 605
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Self-citationCherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Self-citationBaker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Self-citationPessoa, T. D., Campos, L. C. G., Carraro-Lacroix, L., Girardi, A. C. C., & Malnic, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060588 · Cited by 184
Komajda, M., Tavazzi, L., Francq, B. G., Böhm, M., Borer, J. S., Ford, I., & Swedberg, K. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.347 · Cited by 76
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.006 · Cited by 64
Research works printed but not linked: 56
- World Health Organization, 2016, Global Report on Diabetes
- Ray, 2009, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials, Lancet, 373, 1765, 10.1016/S0140-6736(09)60697-8 · DOI · Paper page
- Grundy, 1999, Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation, 100, 1134, 10.1161/01.CIR.100.10.1134 · DOI · Paper page
- Fitchett, 2017, Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes, Eur J Heart Fail, 19, 43, 10.1002/ejhf.633 · DOI
- Lloyd-Jones, 2002, Lifetime risk for developing congestive heart failure: the Framingham Heart Study, Circulation, 106, 3068, 10.1161/01.CIR.0000039105.49749.6F · DOI · Paper page
- Swan, 1997, Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure, J Am Coll Cardiol, 30, 527, 10.1016/S0735-1097(97)00185-X · DOI · Paper page
- Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256 · DOI · Paper page
- Zhou, 2009, Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review, Curr Diabetes Rev, 5, 171, 10.2174/157339909788920938 · DOI
- Dinesh Shah, 2015, Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people, Lancet, 385
- McMurray, 2014, Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored, Lancet Diabetes Endocrinol, 2, 843, 10.1016/S2213-8587(14)70031-2 · DOI · Paper page
- Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
- Lincoff, 2007, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials, JAMA, 298, 1180, 10.1001/jama.298.10.1180 · DOI · Paper page
- McAlister, 2008, The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy, Eur J Heart Fail, 10, 703, 10.1016/j.ejheart.2008.05.013 · DOI
- Rosenstock, 2013, Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial, Diab Vasc Dis Res, 10, 289, 10.1177/1479164112475102 · DOI
- Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 · DOI · Paper page
- Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9 · DOI · Paper page
- Solomon, 2004, Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program, Circulation, 110, 2180, 10.1161/01.CIR.0000144474.65922.AA · DOI · Paper page
- Zile, 2010, Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial, Circulation, 121, 1393, 10.1161/CIRCULATIONAHA.109.909614 · DOI · Paper page
- Cleland, 2006, The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 2338, 10.1093/eurheartj/ehl250 · DOI · Paper page
- Fang, 2016, Heart failure with preserved ejection fraction: a kidney disorder?, Circulation, 134, 435, 10.1161/CIRCULATIONAHA.116.022249 · DOI
- Fitchett, 2017, Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial [abstract], Eur J Heart Fail, 19, 121
- Jorsal, 2017, Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial, Eur J Heart Fail, 19, 69, 10.1002/ejhf.657 · DOI · Paper page
- Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887 · DOI · Paper page
- Nauck, 2014, Update on developments with SGLT2 inhibitors in the management of type 2 diabetes, Drug Des Devel Ther, 8, 1335, 10.2147/DDDT.S50773 · DOI · Paper page
- Sattar, 2016, SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?, Diabetologia, 59, 1333, 10.1007/s00125-016-3956-x · DOI · Paper page
- Inzucchi, 2015, SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials, Diab Vasc Dis Res, 12, 90, 10.1177/1479164114559852 · DOI · Paper page
- Cherney, 2014, Renal hemodynamic effect of sodium–glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 · DOI · Paper page
- Rajasekeran, 2016, Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis, Kidney Int, 89, 524, 10.1016/j.kint.2015.12.038 · DOI
- Heise, 2016, Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes, Clin Ther, 38, 2265, 10.1016/j.clinthera.2016.09.001 · DOI
- Liu, 2014, Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure, Circ Res, 115, 44, 10.1161/CIRCRESAHA.115.303062 · DOI · Paper page
- Layton, 2015, Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition, Am J Physiol Renal Physiol, 308, F1343, 10.1152/ajprenal.00007.2015 · DOI
- Inoue, 2012, Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure, Am J Physiol Regul Integr Comp Physiol, 302, R166, 10.1152/ajpregu.00127.2011 · DOI
- Verbrugge, 2014, The kidney in congestive heart failure: ‘are natriuresis, sodium, and diuretics really the good, the bad and the ugly?’, Eur J Heart Fail, 16, 133, 10.1002/ejhf.35 · DOI · Paper page
- Verbrugge, 2015, SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes?, Curr Cardiovasc Risk Rep, 9, 38, 10.1007/s12170-015-0467-0 · DOI
- Bautista, 2004, Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension, Am J Physiol Renal Physiol, 286, F127, 10.1152/ajprenal.00113.2003 · DOI
- Vasilakou, 2013, Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis, Ann Intern Med, 159, 262, 10.7326/0003-4819-159-4-201308200-00007 · DOI · Paper page
- Riggs, 2015, The use of SGLT-2 inhibitors in type 2 diabetes and heart failure, Metab Syndr Relat Disord, 13, 292, 10.1089/met.2015.0038 · DOI
- Rosengren, 2017, Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden, Eur Heart J, 38, 1926
- Heerspink, 2011, The kidney in type 2 diabetes therapy, Rev Diabet Stud, 8, 392, 10.1900/RDS.2011.8.392 · DOI
- Hamano, 2008, Associations of renal vascular resistance with albuminuria and other macroangiopathy in type 2 diabetic patients, Diabetes Care, 31, 1853, 10.2337/dc08-0168 · DOI
- Lytvyn, 2015, Uric acid as a biomarker and a therapeutic target in diabetes, Can J Diabetes, 39, 239, 10.1016/j.jcjd.2014.10.013 · DOI
- Filippatos, 2011, Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data, Eur Heart J, 32, 712, 10.1093/eurheartj/ehq473 · DOI
- Lytvyn, 2015, Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus, Am J Physiol Renal Physiol, 308, F77, 10.1152/ajprenal.00555.2014 · DOI · Paper page
- Oelze, 2014, The sodium–glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity, PLoS One, 9, 10.1371/journal.pone.0112394 · DOI · Paper page
- Zinman, 2016, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 374, 1094
- Sano, 2016, Increased hematocrit during sodium–glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys, J Clin Med Res, 8, 844, 10.14740/jocmr2760w · DOI · Paper page
- Chang, 2016, Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury, PLoS One, 11
- Tahara, 2013, Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice, Eur J Pharmacol, 715, 246, 10.1016/j.ejphar.2013.05.014 · DOI · Paper page
- Shah, 2012, Increased arterial wave reflection magnitude: a novel form of stage B heart failure?, J Am Coll Cardiol, 60, 2178, 10.1016/j.jacc.2012.07.055 · doi:10.1016/j.jacc.2012.07.055
- Jones, 2012, Minireview: Glucagon in stress and energy homeostasis, Endocrinology, 153, 1049, 10.1210/en.2011-1979 · DOI
- Mery, 1990, Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase, Nature, 345, 158, 10.1038/345158a0 · DOI
- Ferrannini, 2016, Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes, Diabetes, 65, 1190, 10.2337/db15-1356 · DOI · Paper page
- Lopaschuk, 2016, Empagliflozin's fuel hypothesis: not so soon, Cell Metab, 24, 200, 10.1016/j.cmet.2016.07.018 · DOI
- Verma, 2016, Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?, Diabetes Care, 39, e212, 10.2337/dc16-1312 · DOI · Paper page
- Shi, 2017, Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?, Mol Cell Biochem, 10.1007/s11010-017-3018-9 · DOI
- Neal, 2013, Rationale, design, and baseline characteristics of the Canagliflozin cardiovascular assessment study (CANVAS)—a randomized placebo-controlled trial, Am Heart J, 166, 217, 10.1016/j.ahj.2013.05.007 · DOI · Paper page
Cited by
Mullens, W., Damman, K., Harjola, V.-P., Mebazaa, A., Brunner-La Rocca, H.-P., Martens, P., Testani, J. M., Tang, W. H. W., Orso, F., Rossignol, P., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1369 · Cited by 1,119
Self-citationSGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Self-citationNielsen, R., Møller, N., Gormsen, L. C., Tolbod, L. P., Hansson, N. H., Sorensen, J., Harms, H. J., Frøkiær, J., Eiskjaer, H., Jespersen, N. R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036459 · Cited by 518
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Zheng, S. L., Roddick, A. J., Aghar-Jaffar, R., Shun-Shin, M. J., Francis, D., Oliver, N., & Meeran, K. (2018) · JAMA · doi:10.1001/jama.2018.3024 · Cited by 403
Metadata
- Authors
- Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., Kaul, S., Lam, C. S. P., Lip, G. Y. H., Marx, N., McCullough, P. A., Mehta, C. R., Ponikowski, P., Rosenstock, J., Sattar, N., Salsali, A., Scirica, B. M., Shah, S. J., Tsutsui, H., Verma, S., Wanner, C., Woerle, H.-J., Zannad, F., & Anker, S. D.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-24
- Volume
- 19
- Issue
- 11
- Pages
- 1390-1400
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2746903407
- Cited by
- 164
- References
- 31
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.